Tags

Type your tag names separated by a space and hit enter

The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
Biochem Soc Trans. 2021 12 17; 49(6):2879-2890.BS

Abstract

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than 200 million people have been infected with the virus and 4.3 million have lost their lives. Various monoclonal antibodies of human origin that neutralize the SARS-CoV-2 infection have been isolated from convalescent patients for therapeutic and prophylactic purposes. Several vaccines have been developed to restrict the spread of the virus and have been rapidly administered. However, the rollout of vaccines has coincided with the spread of variants of concern. Emerging variants of SARS-CoV-2 present new challenges for therapeutic antibodies and threaten the efficacy of current vaccines. Here, we review the problems faced by neutralizing antibodies and vaccines in the midst of the increasing spread of mutant viruses.

Links

PMC Free PDF

Authors+Show Affiliations

Murano K
Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.
Guo Y
Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.
Siomi H
Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.

MeSH

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansPandemicsSARS-CoV-2Spike Glycoprotein, Coronavirus

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34854887

Citation

Murano, Kensaku, et al. "The Emergence of SARS-CoV-2 Variants Threatens to Decrease the Efficacy of Neutralizing Antibodies and Vaccines." Biochemical Society Transactions, vol. 49, no. 6, 2021, pp. 2879-2890.
Murano K, Guo Y, Siomi H. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. Biochem Soc Trans. 2021;49(6):2879-2890.
Murano, K., Guo, Y., & Siomi, H. (2021). The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. Biochemical Society Transactions, 49(6), 2879-2890. https://doi.org/10.1042/BST20210859
Murano K, Guo Y, Siomi H. The Emergence of SARS-CoV-2 Variants Threatens to Decrease the Efficacy of Neutralizing Antibodies and Vaccines. Biochem Soc Trans. 2021 12 17;49(6):2879-2890. PubMed PMID: 34854887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. AU - Murano,Kensaku, AU - Guo,Youjia, AU - Siomi,Haruhiko, PY - 2021/08/16/received PY - 2021/11/03/revised PY - 2021/11/10/accepted PY - 2021/12/3/pubmed PY - 2022/1/11/medline PY - 2021/12/2/entrez KW - SARS-CoV-2 KW - antibodies KW - variant SP - 2879 EP - 2890 JF - Biochemical Society transactions JO - Biochem Soc Trans VL - 49 IS - 6 N2 - The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than 200 million people have been infected with the virus and 4.3 million have lost their lives. Various monoclonal antibodies of human origin that neutralize the SARS-CoV-2 infection have been isolated from convalescent patients for therapeutic and prophylactic purposes. Several vaccines have been developed to restrict the spread of the virus and have been rapidly administered. However, the rollout of vaccines has coincided with the spread of variants of concern. Emerging variants of SARS-CoV-2 present new challenges for therapeutic antibodies and threaten the efficacy of current vaccines. Here, we review the problems faced by neutralizing antibodies and vaccines in the midst of the increasing spread of mutant viruses. SN - 1470-8752 UR - https://www.unboundmedicine.com/medline/citation/34854887/The_emergence_of_SARS_CoV_2_variants_threatens_to_decrease_the_efficacy_of_neutralizing_antibodies_and_vaccines_ DB - PRIME DP - Unbound Medicine ER -